Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study

Conclusions Subcutaneous treatment with IgPro20 provided long-term benefit at both 0.4 and 0.2 g/kg weekly doses with lower relapse rates on the higher dose. Long-term dosing should be individualized to find the most appropriate dose in a given patient. Classification of evidence This study provides Class IV evidence that for patients with CIDP, long-term treatment with SCIG beyond 24 weeks is safe and efficacious.

http://nn.neurology.org/cgi/content/short/6/5/e590?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - July 2, 2019 Category: Neurology Authors: van Schaik, I. N., Mielke, O., Bril, V., van Geloven, N., Hartung, H.-P., Lewis, R. A., Sobue, G., Lawo, J.-P., Praus, M., Durn, B. L., Cornblath, D. R., Merkies, I. S. J., on behalf of the PATH study group Tags: Chronic inflammatory demyelinating polyneuropathy, Clinical trials Observational study (Cohort, Case control), Class IV Article Source Type: research